+7 (499) 340 10 14

A New Treatment for Lymphoma

European Commission  approved  a new drug (INN obinutusumab) by Roche (a Swiss company) for treatment of follicular lymphoma. The decision is based on results of phase III clinical trials showing effectiveness of treatment with the drug in combination with bendamustin. Further monotherapy with obinutusumab has shown a 52% reduction in the risk of disease or lethal outcome.

LABMGMU LABMGMU +7 (499) 340 10 14 info@labmgmu.ru 119435, Moscow, Malaya Pirogovskay str. 13-1, floor 4